HIND
Vyome Holdings, Inc.NASDAQHealthcare$2.13-0.93%ClosedMarket Cap: $12.0M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.24
P/S
5.01
EV/EBITDA
-2.64
DCF Value
$1.84
FCF Yield
-66.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.3%
Operating Margin
-584.0%
Net Margin
-452.4%
ROE
-365.0%
ROA
-168.9%
ROIC
-373.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $36.6K | $-1.2M | $-0.21 |
| FY 2025 | $319.7K | $-10.3M | $-4.75 |
| Q3 2025 | $34.6K | $-8.6M | $-29.42 |
| Q2 2025 | $1.2M | $-2.6M | $-9.00 |
Trading Activity
Insider Trades
View AllPomichter Stanley D IIIdirector
SellWed Nov 19
Pomichter Stanley D IIIdirector:
SellWed Nov 19
Jolly Mohanjitdirector
SellTue Nov 18
Jolly Mohanjitdirector:
SellTue Nov 18
Tincoff John M. IIIdirector
SellMon Nov 17
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.34
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.